Vusolimogene oderparepvec is under clinical development by Replimune and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Vusolimogene oderparepvec’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 19 Aug 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Vusolimogene oderparepvec Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Vusolimogene oderparepvec overview
RP-1 is under development for the treatment of advanced or metastatic cutaneous squamous cell carcinoma, angiosarcoma, mixed advanced solid tumors including urothelial cell carcinoma, metastatic breast cancer, metastatic uveal melanoma, ocular melanoma, metastatic bladder cancer, non-small cell lung cancer, basal cell carcinoma, squamous cell carcinoma, Merkel cell carcinoma, cutaneous T-cell lymphoma and microsatellite instability high cancers including colorectal and esophageal cancers. RP-1 is used to deliver certain optimized immune activating proteins directly into the immune response-initiating tumor and to draining lymph nodes. The drug candidate is a replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. It is developed based on Immulytic platform. It is administered through intratumor route.
It was under development for the treatment of soft tissue sarcoma.
Replimune, a subsidiary of Replimune Group Inc, is a drug development company that develops oncolytic immunotherapies for the treatment of cancer. The company’s pipeline products include RPI used for treatment of oncolytic immunotherapy backbone, RP2 and RP3for expressing anti-CTLA-4 and co-stimulatory ligands. Its Immulytic platform is designed to maximize systemic immune activation in tumor neoantigens, through viral mediated immunogenic tumor cell killing and deliver optimal combinations of immune activating proteins into tumor and draining lymph nodes. The company operates through healthcare investors located in the UK. Replimune is headquartered in Abingdon, Oxfordshire, the UK.
Quick View Vusolimogene oderparepvec LOA Data
|Highest Development Stage|